Investors

Latest Report

2017 - Q3 Quarterly Report

Prometic reports third quarter 2017 highlights and financial results:
- US $80 million (CAD $100 million) line of credit secured from Structured Alpha LP
- Plasminogen BLA accepted by FDA, PDUFA date fixed at April 14, 2018
- Plasminogen granted rare pediatric disease designation by FDA and priority review status by Health Canada
- PBI-4050 granted Fast Track designation for IPF and green light to initiate the pivotal phase 2/3 clinical trials
- Conference call and live webcast at 11:00 am ET on Tuesday November 14

Download

Annual Report

Annual Report 2016

Building a company to bring safer therapeutic products.

Download Link View all reports

Presentation

Prometic Corporate Presentation January 2017

Experts in bioseparation, plasma derived and small molecule drugs.

Download Link View all presentations
X